Long non-coding RNA ANRIL predicts poor prognosis and promotes invasion/metastasis in serous ovarian cancer

International Journal of Oncology

Volumn 46, Issue 6, 2015, Pages 2497-2505

  Qiu, Jun Jun ^a   Lin, Ying Ying ^b   Ding, Jing Xin ^a   Feng, Wei Wei ^a   Jin, Hong Yan ^a   Hua, Ke Qin ^a  

^a FUDAN UNIVERSITY   (China)

^b SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

ANRIL; Long non coding RNA; Metastasis; Prognosis; Serous ovarian cancer

Indexed keywords

ANTISENSE NON CODING RIBONUCLEIC ACID IN THE INK4 LOCUS; LONG UNTRANSLATED RNA; MESSENGER RNA; SCATTER FACTOR RECEPTOR; SMALL INTERFERING RNA; STROMELYSIN; UNCLASSIFIED DRUG; ANRIL LONG NON-CODING RNA, HUMAN;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SURVIVAL; CELL INVASION; CELL MIGRATION; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GENE LOCUS; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MICROARRAY ANALYSIS; OVARY CANCER; OVERALL SURVIVAL; PREDICTIVE VALUE; PRIORITY JOURNAL; SEROUS OVARIAN CANCER; TUMOR INVASION; WESTERN BLOTTING; AGED; CANCER STAGING; CELL MOTION; CYSTADENOMA; GENE EXPRESSION REGULATION; GENETICS; MIDDLE AGED; OVARY TUMOR; PATHOLOGY; PROGNOSIS; SURVIVAL; TUMOR CELL LINE;

ADULT; AGED; CELL LINE, TUMOR; CELL MOVEMENT; CYSTADENOMA, SEROUS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROGNOSIS; RNA, LONG NONCODING; SURVIVAL ANALYSIS;

EID: 84928532277     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2015.2943     Document Type: Article

References (36)

1. Siegel R, Naishadham D and Jemal A: Cancer statistics, 2012. CA Cancer J Clin 62: 10-29, 2012.
2. Bowtell DD: The genesis and evolution of high-grade serous ovarian cancer. Nat Rev Cancer 10: 803-808, 2010.
3. Feigenberg T, Clarke B, Virtanen C, Plotkin A, Letarte M, Rosen B, Bernardini MQ, Kollara A, Brown TJ and Murphy KJ: Molecular profiling and clinical outcome of high-grade serous ovarian cancer presenting with low-versus high-volume ascites. Biomed Res Int 2014: 367103, 2014.
4. Lengyel E: Ovarian cancer development and metastasis. Am J Pathol 177: 1053-1064, 2010.
5. Rustin G, van der Burg M, Griffin C, Qian W and Swart AM: Early versus delayed treatment of relapsed ovarian cancer. Lancet 377: 380-381, 2011.
6. Wilusz JE, Sunwoo H and Spector DL: Long noncoding RNAs: Functional surprises from the RNA world. Genes Dev 23: 1494-1504, 2009.
7. Nagano T and Fraser P: No-nonsense functions for long noncoding RNAs. Cell 145: 178-181, 2011.
8. Gupta RA, Shah N, Wang KC, Kim J, Horlings HM, Wong DJ, Tsai MC, Hung T, Argani P, Rinn JL, et al: Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 464: 1071-1076, 2010
9. Gutschner T, Hämmerle M, Eissmann M, Hsu J, Kim Y, Hung G, Revenko A, Arun G, Stentrup M, Gross M, et al: The noncoding RNA MALAT1 is a critical regulator of the metastasis phenotype of lung cancer cells. Cancer Res 73: 1180-1189, 2013.
10. Yuan SX, Yang F, Yang Y, Tao QF, Zhang J, Huang G, Yang Y, Wang RY, Yang S, Huo XS, et al: Long noncoding RNA associated with microvascular invasion in hepatocellular carcinoma promotes angiogenesis and serves as a predictor for hepatocellular carcinoma patients' poor recurrence-free survival after hepatectomy. Hepatology 56: 2231-2241, 2012.
11. de Kok JB, Verhaegh GW, Roelofs RW, Hessels D, Kiemeney LA, Aalders TW, Swinkels DW and Schalken JA: DD3(PCA3), a very sensitive and specific marker to detect prostate tumors. Cancer Res 62: 2695-2698, 2002.
12. Sun M, Xia R, Jin F, Xu T, Liu Z, De W and Liu X: Downregulated long noncoding RNA MEG3 is associated with poor prognosis and promotes cell proliferation in gastric cancer. Tumour Biol 35: 1065-1073, 2014.
13. Quagliata L, Matter MS, Piscuoglio S, Arabi L, Ruiz C, Procino A, Kovac M, Moretti F, Makowska Z, Boldanova T, et al: Long noncoding RNA HOTTIP/HOXA13 expression is associated with disease progression and predicts outcome in hepatocellular carcinoma patients. Hepatology 59: 911-923, 2014.
14. Ge X, Chen Y, Liao X, Liu D, Li F, Ruan H and Jia W: Overexpression of long noncoding RNA PCAT-1 is a novel biomarker of poor prognosis in patients with colorectal cancer. Med Oncol 30: 588, 2013.
15. Wang XS, Zhang Z, Wang HC, Cai JL, Xu QW, Li MQ, Chen YC, Qian XP, Lu TJ, Yu LZ, et al: Rapid identification of UCA1 as a very sensitive and specific unique marker for human bladder carcinoma. Clin Cancer Res 12: 4851-4858, 2006.
16. Tano K and Akimitsu N: Long non-coding RNAs in cancer progression. Front Genet 3: 219, 2012.
17. Yu W, Gius D, Onyango P, Muldoon-Jacobs K, Karp J, Feinberg AP and Cui H: Epigenetic silencing of tumour suppressor gene p15 by its antisense RNA. Nature 451: 202-206, 2008.
18. El Messaoudi-Aubert S, Nicholls J, Maertens GN, Brookes S, Bernstein E and Peters G: Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol 17: 862-868, 2010.
19. Pasmant E, Laurendeau I, Héron D, Vidaud M, Vidaud D and Bièche I: Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: Identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67: 3963-3969, 2007.
20. Kotake Y, Nakagawa T, Kitagawa K, Suzuki S, Liu N, Kitagawa M and Xiong Y: Long non-coding RNA ANRIL is required for the PRC2 recruitment to and silencing of p15(INK4B) tumor suppressor gene. Oncogene 30: 1956-1962, 2011.
21. Yap KL, Li S, Muñoz-Cabello AM, Raguz S, Zeng L, Mujtaba S, Gil J, Walsh MJ and Zhou MM: Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662-674, 2010.
22. Turnbull C, Ahmed S, Morrison J, Pernet D, Renwick A, Maranian M, Seal S, Ghoussaini M, Hines S, Healey CS, et al: Breast Cancer Susceptibility Collaboration (UK): Genome-wide association study identifies five new breast cancer susceptibility loci. Nat Genet 42: 504-507, 2010.
23. Chen J, Li D, Wei C, Sen S, Killary AM, Amos CI, Evans DB, Abbruzzese JL and Frazier ML: Aurora-A and p16 polymorphisms contribute to an earlier age at diagnosis of pancreatic cancer in Caucasians. Clin Cancer Res 13: 3100-3104, 2007.
24. Bei JX, Li Y, Jia WH, Feng BJ, Zhou G, Chen LZ, Feng QS, Low HQ, Zhang H, He F, et al: A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci. Nat Genet 42: 599-603, 2010.
25. Stacey SN, Sulem P, Masson G, Gudjonsson SA, Thorleifsson G, Jakobsdottir M, Sigurdsson A, Gudbjartsson DF, Sigurgeirsson B, Benediktsdottir KR, et al: New common variants affecting susceptibility to basal cell carcinoma. Nat Genet 41: 909-914, 2009.
26. Rajaraman P, Melin BS, Wang Z, McKean-Cowdin R, Michaud DS, Wang SS, Bondy M, Houlston R, Jenkins RB, Wrensch M, et al: Genome-wide association study of glioma and meta-analysis. Hum Genet 131: 1877-1888, 2012.
27. Sherborne AL, Hosking FJ, Prasad RB, Kumar R, Koehler R, Vijayakrishnan J, Papaemmanuil E, Bartram CR, Stanulla M, Schrappe M, et al: Variation in CDKN2A at 9p21.3 influences childhood acute lymphoblastic leukemia risk. Nat Genet 42: 492-494, 2010.
28. Yu D, Wolf JK, Scanlon M, Price JE and Hung MC: Enhanced c-erbB-2/neu expression in human ovarian cancer cells correlates with more severe malignancy that can be suppressed by E1A. Cancer Res 53: 891-898, 1993.
29. Bai F, Feng J, Cheng Y, Shi J, Yang R and Cui H: Analysis of gene expression patterns of ovarian cancer cell lines with different metastatic potentials. Int J Gynecol Cancer 16: 202-209, 2006.
30. Wang Y, Dong L, Cui H, Shen DH, Wang Y, Chang XH, Fu TY, Ye X and Yao YY: Up-regulation of mitochondrial antioxidation signals in ovarian cancer cells with aggressive biologic behavior. J Zhejiang Univ Sci B 12: 346-356, 2011.
31. Shenhua X, Lijuan Q, Hanzhou N, Xinghao N, Chihong Z, Gu Z, Weifang D and Yongliang G: Establishment of a highly metastatic human ovarian cancer cell line (HO-8910PM) and its characterization. J Exp Clin Cancer Res 18: 233-239, 1999.
32. Panzitt K, Tschernatsch MM, Guelly C, Moustafa T, Stradner M, Strohmaier HM, Buck CR, Denk H, Schroeder R, Trauner M, et al: Characterization of HULC, a novel gene with striking up-regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterology 132: 330-342, 2007.
33. Du Y, Kong G, You X, Zhang S, Zhang T, Gao Y, Ye L and Zhang X: Elevation of highly up-regulated in liver cancer (HULC) by hepatitis B virus X protein promotes hepatoma cell proliferation via down-regulating p18. J Biol Chem 287: 26302-26311, 2012.
34. Congrains A, Kamide K, Oguro R, Yasuda O, Miyata K, Yamamoto E, Kawai T, Kusunoki H, Yamamoto H, Takeya Y, et al: Genetic variants at the 9p21 locus contribute to atherosclerosis through modulation of ANRIL and CDKN2A/B. Atherosclerosis 220: 449-455, 2012.
35. Sato K, Nakagawa H, Tajima A, Yoshida K and Inoue I: ANRIL is implicated in the regulation of nucleus and potential transcriptional target of E2F1. Oncol Rep 24: 701-707, 2010.
36. Congrains A, Kamide K, Katsuya T, Yasuda O, Oguro R, Yamamoto K, Ohishi M and Rakugi H: CVD-associated non-coding RNA, ANRIL, modulates expression of atherogenic pathways in VSMC. Biochem Biophys Res Commun 419: 612-616, 2012.